Radiopharmaceutical Dosimetry Analytics 2025–2029: Unveiling the Next Wave of Precision & Profit

Table of Contents

• Executive Summary & 2025 Market Snapshot
• Key Drivers: AI, Regulatory Shift, and Imaging Innovation
• Competitive Landscape: Leading Companies and New Entrants
• Technology Advances: Software, Hardware, and Integration Trends
• Application Focus: Oncology, Cardiology, and Emerging Therapeutic Areas
• Dosimetry Standards and Evolving Regulatory Landscape
• Market Forecasts: Revenue, Volume, and Regional Growth to 2029
• Partnerships, M&A, and Strategic Alliances
• Challenges: Data Security, Interoperability, and Workflow Integration
• Future Outlook: Personalized Medicine, Automation, and Next-Gen Analytics
• Sources & References

Executive Summary & 2025 Market Snapshot

Radiopharmaceutical dosimetry analytics is experiencing significant momentum in 2025, driven by rapid advancements in molecular imaging, personalized medicine, and the expanding clinical adoption of targeted radiopharmaceutical therapies. Dosimetry analytics—encompassing the measurement and modeling of radiation dose distribution within the body—remains pivotal for optimizing treatment efficacy, minimizing toxicity, and ensuring regulatory compliance for both diagnostic and therapeutic radiopharmaceuticals. In 2025, the integration of advanced analytics platforms, artificial intelligence (AI), and quantitative imaging tools is accelerating the transition from population-based to patient-specific dosing paradigms.

Major industry players—such as GE HealthCare, Siemens Healthineers, and Varian (a Siemens Healthineers company)—are expanding their portfolios of dosimetry software and analytics solutions to support the increasing adoption of theranostics, particularly in oncology. The FDA’s recent approvals of radiopharmaceuticals for prostate cancer and neuroendocrine tumors have heightened the necessity for precise, individualized dosimetry, with leading hospitals and cancer centers deploying commercial solutions such as Mirada Medical’s dosimetry platforms and MIM Software Inc.’s quantitative analysis tools in routine clinical workflows.

Key trends shaping the 2025 market include:

• Widespread clinical integration of SPECT/CT and PET/CT imaging data with AI-driven analytics for quantitative dose assessment, as exemplified by collaborations between Siemens Healthineers and leading academic centers.
• Regulatory and reimbursement frameworks in the US and Europe increasingly recognizing the clinical and economic value of personalized dosimetry, encouraging broader adoption of dosimetry analytics for both commercial and investigational radiopharmaceuticals, as highlighted by updates from the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
• Ongoing development of cloud-based dosimetry platforms and seamless integration with hospital information systems, with solutions from Mirada Medical and MIM Software Inc. enabling multi-center data sharing and real-time analytics for clinical trials and routine care.

Looking ahead, the outlook for radiopharmaceutical dosimetry analytics over the next few years is strongly positive. Market growth is anticipated to be driven by the expanding pipeline of targeted radiopharmaceuticals in oncology and cardiology, ongoing technological innovation, and increasing alignment of regulatory standards with personalized medicine initiatives. Strategic partnerships between technology developers, pharmaceutical manufacturers, and clinical providers will further enhance the accessibility and clinical impact of dosimetry analytics worldwide.

Key Drivers: AI, Regulatory Shift, and Imaging Innovation

The landscape of radiopharmaceutical dosimetry analytics is undergoing rapid transformation in 2025, propelled by three key drivers: artificial intelligence (AI), regulatory changes, and advances in imaging technology. These forces are converging to enhance precision in dose estimation, optimize patient outcomes, and streamline compliance in nuclear medicine.

• Artificial Intelligence and Automation: AI and machine learning are at the forefront of innovation, enabling faster and more accurate dosimetry calculations. In early 2025, Siemens Healthineers introduced AI-powered modules within their syngo.via platform, automating segmentation and quantification from PET/CT images. Likewise, GE HealthCare has expanded its suite of analytics tools to include AI-driven workflows for radiopharmaceutical therapy planning. These technologies significantly reduce manual workload and inter-operator variability while supporting individualized treatment approaches.
• Regulatory Shift Toward Personalized Dosimetry: Regulatory agencies are mandating more rigorous and patient-specific dosimetry, especially as novel theranostic agents like lutetium-177 and actinium-225 gain approval. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are emphasizing risk-based approaches and post-market surveillance for radiopharmaceuticals, requiring advanced analytics for compliance (European Medicines Agency). In response, industry players such as Bayer and Abbott are investing in dosimetry software that supports dynamic adaptation to regulatory expectations, including real-time dose reporting and audit trails.
• Imaging Innovation and Quantitative Analytics: Next-generation imaging systems are driving improvements in spatial and temporal resolution, directly impacting dosimetry accuracy. Canon Medical Systems and Philips have released SPECT/CT and PET/CT platforms in 2025 with advanced quantitative capabilities, enabling precise measurement of radiopharmaceutical distribution and kinetics. These platforms are increasingly integrated with dosimetry analytics, facilitating robust multi-timepoint data collection—a prerequisite for accurate personalized dosimetry.

Looking ahead, the synergy of AI, evolving regulatory requirements, and imaging advancements will continue to refine dosimetry analytics, supporting the expansion of radiopharmaceutical therapies into broader oncology and rare disease indications. As industry leaders collaborate on interoperability and standardization, these drivers are poised to deliver safer, more effective, and compliant nuclear medicine solutions in the coming years.

Competitive Landscape: Leading Companies and New Entrants

The competitive landscape for radiopharmaceutical dosimetry analytics is rapidly evolving as precision medicine, regulatory expectations, and advanced imaging technologies drive demand for more accurate, patient-specific dosing. In 2025, established leaders and innovative new entrants are shaping a dynamic market focused on improving clinical outcomes in nuclear medicine and radiotherapy.

• Leading Companies:
  • Siemens Healthineers continues to dominate the dosimetry analytics market with its integrated molecular imaging solutions and advanced analytics software. Their syngo.via platform supports quantitative SPECT and PET analysis, enabling clinicians to deploy individualized dosimetry workflows across a wide range of theranostic applications.
  • GE HealthCare leverages its PET/CT and SPECT/CT systems in combination with the Dosimetry Toolkit to provide end-to-end solutions for radiopharmaceutical therapy planning and monitoring. The company’s focus on AI-driven analytics and cloud-based data management further strengthens its competitive position.
  • Varian, a Siemens Healthineers company offers the Velocity platform, which integrates imaging and dosimetry data for precise treatment planning in targeted radionuclide therapy. Its robust analytics are increasingly adopted in major clinical centers.
  • Mirada Medical specializes in AI-powered dosimetry software, such as its Dosimetry+ solution, supporting multi-isotope therapy planning and facilitating compliance with evolving European and US regulations.
• New Entrants and Innovators:
  • Dosimetry Solutions is a notable startup, offering cloud-based, vendor-neutral platforms for automated dosimetry calculation and workflow optimization, which are gaining traction among radiopharmacies and smaller clinics.
  • Advacam and other imaging technology developers are entering the analytics space by integrating proprietary detector technology with advanced dose quantification software, aiming to improve accuracy and efficiency in personalized radiopharmaceutical therapy.
• Outlook (2025 and Beyond):
  • Regulatory pressures, such as the European Council Directive 2013/59/Euratom requiring individualized dosimetry, continue to accelerate adoption of advanced analytics platforms.
  • Partnerships between radiopharmaceutical manufacturers, imaging companies, and healthcare providers are expected to intensify, fostering interoperability and the creation of unified, AI-powered dosimetry ecosystems.
  • Ongoing clinical trials and the anticipated approval of new radiotherapeutics (e.g., targeted alpha therapies) will likely expand the addressable market, drawing further investment and new entrants into analytics solutions tailored for emerging therapies.

Technology Advances: Software, Hardware, and Integration Trends

Radiopharmaceutical dosimetry analytics are undergoing a transformative phase, driven by rapid advancements in both software and hardware, as well as the increasing integration of these technologies into clinical workflows. In 2025 and the coming years, several key trends and developments are shaping this landscape.

• Artificial Intelligence and Machine Learning Integration: The adoption of AI and machine learning is accelerating in dosimetry analytics. These technologies are being used to automate lesion segmentation, personalize dose calculations, and predict patient-specific pharmacokinetics. For instance, GE HealthCare and Siemens Healthineers have incorporated AI-powered tools into their molecular imaging platforms, enabling more accurate quantification and faster analysis of SPECT and PET images.
• Cloud-Based Dosimetry Platforms: Cloud computing is becoming a standard for data storage, processing, and collaboration. Companies like Mirada Medical and Spectra Medix offer cloud-based dosimetry solutions, allowing remote access, real-time collaboration, and secure sharing of patient data for multi-center studies and clinical trials.
• Automated Multi-Modality Image Registration: The accuracy of dosimetry analytics depends on precise image registration across modalities (PET/CT, SPECT/CT, MRI). Vendors such as Mirada Medical and Siemens Healthineers are advancing automated registration tools, improving reproducibility and reducing user dependency.
• Personalized Dosimetry and Theranostics: The shift toward personalized radiopharmaceutical therapy is driving demand for individualized dosimetry. SOPHiA GENETICS and GE HealthCare are developing analytics platforms that integrate genomic and imaging data for enhanced treatment planning and outcome prediction.
• Regulatory and Interoperability Initiatives: Efforts to standardize dosimetry workflows and ensure interoperability across imaging systems are ongoing. Organizations like the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are actively working on guidelines and open data standards to facilitate seamless integration of dosimetry analytics into electronic health records and hospital information systems.

Looking ahead, the convergence of AI, cloud infrastructure, and personalized medicine is expected to further streamline radiopharmaceutical dosimetry analytics, improving clinical decision-making and patient outcomes. Continued collaboration among technology providers, healthcare institutions, and regulatory bodies will be essential to realize the full potential of these innovations in routine practice.

Application Focus: Oncology, Cardiology, and Emerging Therapeutic Areas

Radiopharmaceutical dosimetry analytics—quantitative methodologies for estimating absorbed radiation doses in tissues—are rapidly gaining prominence across oncology, cardiology, and emerging therapeutic areas in 2025. These analytics underpin precision medicine approaches, optimizing the efficacy and safety of targeted radiopharmaceutical therapies.

In oncology, the shift toward theranostics—integrated diagnostic and therapeutic radiopharmaceuticals—demands highly accurate dosimetry. Lutetium-177 (Lu-177)-based therapies, such as Novartis‘s Lutathera for neuroendocrine tumors and Pluvicto for metastatic prostate cancer, are driving the need for individualized dosimetry to maximize tumor irradiation while sparing healthy tissues. 2025 sees increased collaboration between industry and academic centers to standardize quantitative SPECT/CT and PET/CT imaging protocols, as supported by the efforts of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Cardiology applications focus on non-invasive imaging agents, with analytics enabling more precise assessment of myocardial perfusion and viability. Companies such as Bracco are advancing cardiac SPECT agents, while analytics platforms increasingly integrate AI to streamline quantitative analysis and improve reproducibility. Standardization and regulatory harmonization, championed by bodies like the International Atomic Energy Agency (IAEA), are crucial for widespread clinical adoption.

Emerging therapeutic areas include radiopharmaceuticals targeting rare cancers, infectious diseases, and neurodegenerative disorders. For example, Telix Pharmaceuticals is exploring radioligand therapies for glioblastoma and other challenging indications. Dosimetry analytics are essential for early-phase trials to establish safety profiles and inform dosing regimens. Integration of advanced modeling software and digital health tools is accelerating, exemplified by Mirion Technologies‘ dosimetry systems, which are being adopted in both research and clinical settings.

Looking forward, 2025 and the following years will likely see the expansion of centralized dosimetry analytics platforms, cloud-based data sharing, and machine learning-enhanced protocols. Regulatory frameworks are evolving to mandate more rigorous dosimetry in clinical trials, as highlighted by updates from the U.S. Food and Drug Administration (FDA). The convergence of imaging, data analytics, and AI is poised to transform dosimetry from a specialized research tool into a routine component of personalized care across oncology, cardiology, and beyond.

Dosimetry Standards and Evolving Regulatory Landscape

Radiopharmaceutical dosimetry analytics are undergoing significant transformation in 2025, driven by the convergence of emerging standards and a dynamic regulatory environment. Historically, dosimetry in nuclear medicine relied on population-based models and generalized absorbed dose estimation, often leading to variability in patient outcomes. In recent years, however, the shift towards patient-specific dosimetry has been catalyzed by the increasing complexity of theranostic radiopharmaceuticals and the need for precision medicine.

Regulatory agencies are playing a pivotal role in shaping dosimetry practices. The U.S. Food and Drug Administration (FDA) has underscored the necessity of robust dosimetry data in investigational new drug applications for radiopharmaceuticals, particularly for targeted alpha therapies and novel beta emitters. In Europe, the European Medicines Agency (EMA) and European Association of Nuclear Medicine (EANM) continue to refine guidelines to standardize dosimetry protocols for both clinical trials and routine practice.

The last year has seen several industry collaborations aimed at harmonizing dosimetry standards globally. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has partnered with international stakeholders to release consensus documents on image-based dosimetry and quantitative SPECT/CT and PET/CT methodologies, which are increasingly required in regulatory submissions. Furthermore, the International Atomic Energy Agency (IAEA) is actively updating its technical guidance to support low- and middle-income countries in meeting these evolving standards.

Technological advancements are also shaping regulatory expectations. Vendors such as Siemens Healthineers, GE HealthCare, and SOPHiA GENETICS are integrating advanced analytics into their imaging and software platforms, enabling more accurate and reproducible absorbed dose calculations. These innovations not only support compliance with emerging regulatory requirements but also facilitate multicenter clinical trials by ensuring data interoperability and traceability.

Looking ahead, the next few years are expected to bring further convergence between regulatory guidance and technological capability. The adoption of artificial intelligence and machine learning for automated dosimetry workflows is anticipated to accelerate, with ongoing pilot programs and validation studies supported by both academic and industry consortia. Additionally, the growing focus on real-world evidence by regulatory bodies will likely result in novel post-marketing surveillance requirements for radiopharmaceutical dosimetry—further emphasizing the need for standardized, analytics-driven approaches across the sector.

Market Forecasts: Revenue, Volume, and Regional Growth to 2029

The global market for radiopharmaceutical dosimetry analytics is poised for significant expansion through 2029, propelled by the growing adoption of targeted radionuclide therapies, increasing regulatory scrutiny, and advances in imaging and software analytics. Dosimetry analytics, which optimize the calculation of absorbed radiation dose for individual patients, are becoming critical for both clinical outcomes and regulatory compliance in nuclear medicine.

As of 2025, North America remains the largest market, driven by advanced healthcare infrastructure and the rapid uptake of radiopharmaceuticals for cancer diagnostics and therapy. Companies such as Mirion Technologies and Siemens Healthineers are expanding their analytics portfolios, supporting robust hospital and research demand. Europe follows closely, benefiting from harmonized regulatory frameworks and extensive clinical trials in theranostics.

Asia-Pacific is forecasted to exhibit the fastest compound annual growth rate (CAGR) through 2029, as countries like Japan, South Korea, and India accelerate investments in precision oncology and nuclear medicine infrastructure. Regional collaborations and technology transfers—such as partnerships between local providers and international leaders like GE HealthCare—are expected to further stimulate volume growth and market penetration.

By 2029, annual global revenue from radiopharmaceutical dosimetry analytics is anticipated to exceed USD 1.2 billion, with an expected CAGR of approximately 12–15% between 2025 and 2029. Growth is underpinned by the increasing number of approved radiotherapeutics, expanded indications for existing agents, and the integration of artificial intelligence (AI) into dosimetry workflows. Companies such as EKL Medical and Mirai Medical are introducing cloud-based and AI-powered solutions, enabling higher throughput and standardized analytics.

• Volume trends: The number of dosimetry procedures performed globally is projected to grow by over 15% annually, reflecting both increased therapy volumes and greater regulatory emphasis on personalized dosimetry.
• Regional outlook: North America and Europe will continue to dominate revenue through established healthcare networks, but Asia-Pacific will lead in procedure volume growth due to new installations and expanding patient access.
• Market drivers: Key drivers include regulatory mandates for dosimetry in radiopharmaceutical therapy, technological advances in quantitative imaging, and the need for reproducible, patient-specific dose planning.

Looking ahead, the competitive landscape is expected to intensify, with major imaging and software vendors, as well as specialized analytics firms, investing in new platforms and partnerships to capture expanding clinical and research markets worldwide.

Partnerships, M&A, and Strategic Alliances

Radiopharmaceutical dosimetry analytics is witnessing a surge in partnerships, mergers and acquisitions (M&A), and strategic alliances as leading industry players seek to bolster their capabilities in precision medicine and personalized diagnostics. The increasing clinical adoption of radioligand therapies and targeted radionuclide treatments has intensified the demand for advanced dosimetry tools, driving companies to collaborate and consolidate expertise across imaging, software, and pharmaceutical development.

One of the most significant drivers of recent alliances is the integration of dosimetry analytics with advanced imaging and therapy platforms. For example, GE HealthCare has established collaborations with radiopharmaceutical developers and AI software companies to co-develop imaging analytics solutions that support patient-specific dosimetry for both clinical and research applications. Similarly, Siemens Healthineers has entered into partnerships with radiopharmaceutical manufacturers to embed their imaging and analytics platforms into theranostic workflows, aiming to streamline quantitative dosimetry in nuclear medicine.

Strategic acquisitions have also shaped the landscape in 2025. Bracco has expanded its portfolio in quantitative imaging by acquiring companies specializing in dosimetry analytics, thereby enhancing its offering for theranostic procedures and strengthening its position in the radiopharmaceutical sector. In parallel, Bayer has announced joint ventures with dosimetry software providers to integrate real-time dose monitoring solutions into its radiopharmaceutical therapies, reflecting a broader industry move toward end-to-end digitalization of nuclear medicine workflows.

In the next few years, cross-industry alliances between pharmaceutical companies, imaging technology vendors, and health IT firms are anticipated to accelerate. These collaborations aim to create interoperable dosimetry platforms, improve regulatory compliance, and facilitate multi-center clinical trials by standardizing quantitative dosimetry protocols. Notably, industry consortia such as the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are fostering global partnerships between academic institutions, manufacturers, and healthcare providers to advance best practices and harmonize dosimetry analytics standards.

Looking ahead, as personalized radiopharmaceutical therapies become mainstream, the pace of strategic alliances, co-development agreements, and technology-driven partnerships is expected to intensify, with a focus on integrating AI, cloud-based analytics, and advanced imaging to enable precise, patient-specific dosimetry across the care continuum.

Challenges: Data Security, Interoperability, and Workflow Integration

Radiopharmaceutical dosimetry analytics is advancing rapidly, but several key challenges persist in 2025 and are projected to shape the landscape over the next few years. Chief among these are data security, interoperability, and seamless integration into clinical workflows.

Data security is paramount, as dosimetry analytics platforms process sensitive patient information and proprietary imaging data. The adoption of cloud-based analytics and remote collaboration solutions—accelerated by the need for multi-institutional trials—has increased the sector’s vulnerability to cyber threats. Industry leaders like Siemens Healthineers and GE HealthCare are enhancing their radiopharmaceutical dosimetry platforms with advanced encryption, role-based access controls, and compliance with international regulations such as HIPAA and GDPR. However, ensuring end-to-end security, particularly when integrating third-party AI modules or connecting to external hospital information systems, remains a persistent challenge.

Interoperability is another significant hurdle. Radiopharmaceutical dosimetry analytics frequently involves the aggregation and analysis of heterogeneous data from imaging modalities (PET, SPECT, CT), radiopharmacy information, and electronic health records (EHRs). The lack of standardized data formats and semantics can impede accurate data exchange and limit cross-platform compatibility. Efforts are underway by organizations such as Society of Nuclear Medicine and Molecular Imaging (SNMMI) and vendors like Hermes Medical Solutions to promote DICOM and HL7/FHIR standards adoption. Despite progress, full semantic interoperability—especially for complex dosimetric calculations and longitudinal patient tracking—remains elusive, and is expected to be a focus for industry consortia and regulatory agencies through 2027.

Workflow integration is critical for the clinical adoption of advanced dosimetry analytics. Solutions must fit seamlessly into existing radiology and nuclear medicine workflows without imposing undue technical or administrative burdens. Companies such as Mirada Medical and SOPHiA GENETICS are developing modular analytics platforms designed for interoperability with PACS, RIS, and EHR systems. However, challenges persist in automating data transfer, maintaining audit trails, and supporting real-time decision-making at the point of care. The next few years are likely to see further collaboration between vendors and healthcare providers, with a focus on robust APIs, plug-and-play software modules, and user-friendly interfaces to drive broader adoption and optimize patient outcomes.

Future Outlook: Personalized Medicine, Automation, and Next-Gen Analytics

Radiopharmaceutical dosimetry analytics is transitioning rapidly, driven by the convergence of personalized medicine, automation, and next-generation analytical techniques. In 2025 and the immediate years ahead, several pivotal trends are shaping the landscape of how doses are calculated, optimized, and validated for both diagnostic and therapeutic radiopharmaceuticals.

A central development is the move toward personalized dosimetry, moving away from “one-size-fits-all” activity prescriptions. Companies such as Siemens Healthineers and GE HealthCare are integrating AI-driven imaging analytics and kinetic modeling into their clinical platforms, enabling individualized dose calculations based on real-time patient physiology and tumor uptake. This personalization is expected to improve therapeutic efficacy and reduce toxicity, especially in rapidly growing indications like neuroendocrine tumors and prostate cancer.

Automation is another key trend, with vendors such as Mirada Medical and SOPHiA GENETICS introducing cloud-based and AI-enabled software tools that streamline the dosimetry workflow. These solutions automate image segmentation, time-activity curve fitting, and absorbed dose calculations, addressing the bottlenecks of manual analysis and reducing inter-operator variability. In 2025, wider deployment of such platforms is anticipated as regulatory guidance from bodies like the FDA and EMA increasingly endorses quantitative post-therapy verification for radioligand and alpha therapies.

The next few years will also see advances in multi-modality analytics, combining quantitative data from SPECT/CT, PET/CT, and even digital pathology, to refine dose mapping at a sub-organ or even cellular level. Sirona Medical and Varian are actively exploring these integrations, seeking to link imaging biomarkers with genomics and radiomics for truly individualized therapy planning.

• By 2025, AI-based dosimetry will become increasingly routine for theranostics in leading nuclear medicine centers.
• Automated, cloud-delivered platforms are expected to dominate new installations, supporting both local and remote expert review.
• Regulators and professional societies, including the Society of Nuclear Medicine and Molecular Imaging (SNMMI), are anticipated to formalize guidelines on patient-specific dosimetry documentation and quality assurance.

As reimbursement models evolve and real-world evidence accumulates, radiopharmaceutical dosimetry analytics will be integral to the safe, effective, and personalized delivery of next-generation radiotherapies.

Sources & References

• GE HealthCare
• Siemens Healthineers
• Varian (a Siemens Healthineers company)
• Mirada Medical
• MIM Software Inc.
• European Medicines Agency
• Philips
• Dosimetry Solutions
• Advacam
• Spectra Medix
• Novartis
• Bracco
• International Atomic Energy Agency
• Mirion Technologies
• European Association of Nuclear Medicine (EANM)
• Mirai Medical
• Hermes Medical Solutions
• SOPHiA GENETICS